OPKO Health Q4 revenue $181.9M; net loss narrows to $0.09/sh; $230M convertible notes issued

OPKO HEALTH, INC.

2025-FY EPS reported -$0.25 vs consensus -$0.07 ▼ miss (-260.8%)

Consolidated revenue $181.9M vs $185.4M in prior-year quarter; net loss $65.5M ($0.09/sh) vs $85.2M ($0.11/sh).
Diagnostics segment revenue fell 11% to $124.2M on lower reimbursement and COVID-19 testing decline.
Pharmaceuticals revenue rose to $43.0M, driven by international operations and RAYALDEE sales of $9.3M.
After quarter end, OPKO sold $230M of 3.75% convertible senior notes due 2029 and used $50M to repurchase stock.
BioReference Health REACH program reduced annualized expenses by $10.1M; operating loss $42.3M including $4.7M non-recurring.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OPKO HEALTH, INC. reported three and 12 months ended December 31, 2023 results: revenue $181.9 million, net income Net loss for the fourth quarter of 2023 was $65.5 million, or $0.09 per share, EPS $0.09 per share.

Period: three and 12 months ended December 31, 2023
Revenue: $181.9 million
Net income: Net loss for the fourth quarter of 2023 was $65.5 million, or $0.09 per share
EPS: $0.09 per share
Result: reported results

Exact text from the filing

of revenue adjustments, compared with an operating loss of $23.1 million in the 2022 period. ● Consolidated: Consolidated total revenues for the fourth quarter of 2023 were $181.9 million compared with $185.4 million for the comparable 2022 period. Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for

View on SEC.gov

Browse all earnings releases →

OPKO HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-005707

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.